{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T05:28:46Z","timestamp":1794979726373,"version":"4.9.1"},"reference-count":121,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T00:00:00Z","timestamp":1717459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T00:00:00Z","timestamp":1717459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"GSK Biologicals SA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s40121-024-00990-7","type":"journal-article","created":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T14:03:38Z","timestamp":1717509818000},"page":"1439-1459","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["Herpes Zoster Ophthalmicus: Presentation, Complications, Treatment, and Prevention"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3103-0064","authenticated-orcid":false,"given":"John","family":"Litt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6744-5667","authenticated-orcid":false,"given":"Anthony L.","family":"Cunningham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1229-2018","authenticated-orcid":false,"given":"Francisco","family":"Arnalich-Montiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8412-307X","authenticated-orcid":false,"given":"Raunak","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,4]]},"reference":[{"issue":"4","key":"990_CR1","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1177\/2051013615599151","volume":"3","author":"RW Johnson","year":"2015","unstructured":"Johnson RW, Alvarez-Pasquin MJ, Bijl M, et al. Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective. Ther Adv Vaccines. 2015;3(4):109\u201320.","journal-title":"Ther Adv Vaccines"},{"issue":"108","key":"990_CR2","first-page":"71","volume":"33","author":"S Tuft","year":"2020","unstructured":"Tuft S. How to manage herpes zoster ophthalmicus. Community Eye Health. 2020;33(108):71\u20132.","journal-title":"Community Eye Health"},{"issue":"1","key":"990_CR3","first-page":"55","volume":"18","author":"GE Gross","year":"2020","unstructured":"Gross GE, Eisert L, Doerr HW, et al. S2k guidelines for the diagnosis and treatment of herpes zoster and postherpetic neuralgia. J Dtsch Dermatol Ges. 2020;18(1):55\u201378.","journal-title":"J Dtsch Dermatol Ges"},{"issue":"1","key":"990_CR4","first-page":"123","volume":"17","author":"M Tsatsos","year":"2022","unstructured":"Tsatsos M, Athanasiadis I, Myrou A, Saleh MG, Ziakas N. Herpes zoster ophthalmicus: a devastating disease coming back with vengeance or finding its nemesis? J Ophthalmic Vis Res. 2022;17(1):123\u20139.","journal-title":"J Ophthalmic Vis Res"},{"issue":"22","key":"990_CR5","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1056\/NEJMoa051016","volume":"352","author":"MN Oxman","year":"2005","unstructured":"Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352(22):2271\u201384.","journal-title":"N Engl J Med"},{"issue":"7","key":"990_CR6","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1093\/cid\/cir970","volume":"54","author":"KE Schmader","year":"2012","unstructured":"Schmader KE, Levin MJ, Gnann JW Jr., et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50\u201359\u00a0years. Clin Infect Dis. 2012;54(7):922\u20138.","journal-title":"Clin Infect Dis"},{"issue":"22","key":"990_CR7","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","volume":"372","author":"H Lal","year":"2015","unstructured":"Lal H, Cunningham AL, Godeaux O, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372(22):2087\u201396.","journal-title":"N Engl J Med"},{"issue":"11","key":"990_CR8","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","volume":"375","author":"AL Cunningham","year":"2016","unstructured":"Cunningham AL, Lal H, Kovac M, et al. Efficacy of the herpes zoster subunit vaccine in adults 70\u00a0years of age or older. N Engl J Med. 2016;375(11):1019\u201332.","journal-title":"N Engl J Med"},{"key":"990_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.978203","volume":"13","author":"Y Xia","year":"2022","unstructured":"Xia Y, Zhang X, Zhang L, Fu C. Efficacy, effectiveness, and safety of herpes zoster vaccine in the immunocompetent and immunocompromised subjects: a systematic review and network meta-analysis. Front Immunol. 2022;13:978203.","journal-title":"Front Immunol"},{"issue":"10","key":"990_CR10","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/j.amjmed.2016.08.008","volume":"129","author":"L Herman","year":"2016","unstructured":"Herman L, Levin MJ, Rehm S. Shedding light on shingles: the power of prevention. Am J Med. 2016;129(10):1137.","journal-title":"Am J Med"},{"issue":"1","key":"990_CR11","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s40121-021-00567-8","volume":"11","author":"D Curran","year":"2022","unstructured":"Curran D, Callegaro A, Fahrbach K, et al. Meta-regression of herpes zoster incidence worldwide. Infect Dis Ther. 2022;11(1):389\u2013403.","journal-title":"Infect Dis Ther"},{"issue":"5","key":"990_CR12","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1097\/00005792-198209000-00003","volume":"61","author":"MW Ragozzino","year":"1982","unstructured":"Ragozzino MW, Melton LJ 3rd, Kurland LT, Chu CP, Perry HO. Population-based study of herpes zoster and its sequelae. Medicine (Baltimore). 1982;61(5):310\u20136.","journal-title":"Medicine (Baltimore)"},{"issue":"11","key":"990_CR13","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.4065\/82.11.1341","volume":"82","author":"BP Yawn","year":"2007","unstructured":"Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc. 2007;82(11):1341\u20139.","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"990_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-004833","volume":"4","author":"K Kawai","year":"2014","unstructured":"Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014;4(6):e004833.","journal-title":"BMJ Open"},{"issue":"6","key":"990_CR15","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1093\/cid\/ciw854","volume":"64","author":"HS Izurieta","year":"2017","unstructured":"Izurieta HS, Wernecke M, Kelman J, et al. Effectiveness and duration of protection provided by the live-attenuated herpes zoster vaccine in the medicare population ages 65\u00a0years and older. Clin Infect Dis. 2017;64(6):785\u201393.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"990_CR16","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.ophtha.2019.10.001","volume":"127","author":"CL Kong","year":"2020","unstructured":"Kong CL, Thompson RR, Porco TC, Kim E, Acharya NR. Incidence rate of herpes zoster ophthalmicus: a retrospective cohort study from 1994 through 2018. Ophthalmology. 2020;127(3):324\u201330.","journal-title":"Ophthalmology"},{"issue":"3","key":"990_CR17","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.jcjo.2023.04.011","volume":"59","author":"AA Dmitriev","year":"2024","unstructured":"Dmitriev AA, Odden J, Mora-Boellstorff D, et al. Herpes zoster ophthalmicus: frequency and risk factors for developing uncommon ocular manifestations. Can J Ophthalmol. 2024;59(3):201\u20137.","journal-title":"Can J Ophthalmol"},{"issue":"9","key":"990_CR18","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.annepidem.2005.12.002","volume":"16","author":"W Opstelten","year":"2006","unstructured":"Opstelten W, Van Essen GA, Schellevis F, Verheij TJM, Moons KGM. Gender as an independent risk factor for herpes zoster: a population-based prospective study. Ann Epidemiol. 2006;16(9):692\u20135.","journal-title":"Ann Epidemiol"},{"issue":"2","key":"990_CR19","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/21645515.2017.1264834","volume":"13","author":"C Alicino","year":"2017","unstructured":"Alicino C, Trucchi C, Paganino C, et al. Incidence of herpes zoster and post-herpetic neuralgia in Italy: results from a 3-years population-based study. Hum Vaccin Immunother. 2017;13(2):399\u2013404.","journal-title":"Hum Vaccin Immunother"},{"key":"990_CR20","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ijid.2021.12.332","volume":"116","author":"C Cifuentes-Gonzalez","year":"2022","unstructured":"Cifuentes-Gonzalez C, Rojas-Carabali W, Fonseca-Mora MA, Mejia-Salgado G, Reyes-Guanes J, de-la-Torre A. Colombian Ocular Infectious Epidemiology Study (COIES): herpes zoster ophthalmicus prevalence and sociodemographic characterization, 2015\u20132019. Int J Infect Dis. 2022;116:27\u201333.","journal-title":"Int J Infect Dis"},{"issue":"3","key":"990_CR21","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.ophtha.2012.09.007","volume":"120","author":"DS Borkar","year":"2013","unstructured":"Borkar DS, Tham VM, Esterberg E, et al. Incidence of herpes zoster ophthalmicus: results from the Pacific Ocular Inflammation Study. Ophthalmology. 2013;120(3):451\u20136.","journal-title":"Ophthalmology"},{"key":"990_CR22","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s12879-016-1369-6","volume":"16","author":"SA Schmidt","year":"2016","unstructured":"Schmidt SAJ, Kahlert J, Vestergaard M, Schonheyder HC, Sorensen HT. Hospital-based herpes zoster diagnoses in Denmark: rate, patient characteristics, and all-cause mortality. BMC Infect Dis. 2016;16:99.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"990_CR23","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa005","volume":"7","author":"F Marra","year":"2020","unstructured":"Marra F, Parhar K, Huang B, Vadlamudi N. Risk factors for herpes zoster infection: a meta-analysis. Open Forum Infect Dis. 2020;7(1):ofaa005.","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"990_CR24","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s10792-021-02058-8","volume":"42","author":"R Dammacco","year":"2022","unstructured":"Dammacco R, Guerriero S, Alessio G, Dammacco F. Natural and iatrogenic ocular manifestations of rheumatoid arthritis: a systematic review. Int Ophthalmol. 2022;42(2):689\u2013711.","journal-title":"Int Ophthalmol"},{"issue":"1","key":"990_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-014032","volume":"7","author":"TL Liao","year":"2017","unstructured":"Liao TL, Chen YM, Liu HJ, Chen DY. Risk and severity of herpes zoster in patients with rheumatoid arthritis receiving different immunosuppressive medications: a case-control study in Asia. BMJ Open. 2017;7(1):e014032.","journal-title":"BMJ Open"},{"key":"990_CR26","volume":"2015","author":"G Sharew","year":"2015","unstructured":"Sharew G, Azage M. Predictors of HIV\/AIDS related ocular manifestations among HIV\/AIDS patients in Felege Hiwot Referral Hospital, Northwest Ethiopia. J Ophthalmol. 2015;2015:965627.","journal-title":"Northwest Ethiopia J Ophthalmol"},{"issue":"2","key":"990_CR27","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1177\/0956462412472303","volume":"24","author":"S Nithyanandam","year":"2013","unstructured":"Nithyanandam S, Joseph M, Stephen J. Ocular complications and loss of vision due to herpes zoster ophthalmicus in patients with HIV infection and a comparison with HIV-negative patients. Int J STD AIDS. 2013;24(2):106\u20139.","journal-title":"Int J STD AIDS"},{"issue":"1","key":"990_CR28","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1086\/516285","volume":"26","author":"LD Ormerod","year":"1998","unstructured":"Ormerod LD, Larkin JA, Margo CA, et al. Rapidly progressive herpetic retinal necrosis: a blinding disease characteristic of advanced AIDS. Clin Infect Dis. 1998;26(1):34\u201345 (discussion 6\u20137).","journal-title":"Clin Infect Dis"},{"key":"990_CR29","unstructured":"Taney L, Shah VA, Shah VA, et al. EyeWiki. Acute retinal necrosis. American Academy of Ophthalmology. https:\/\/eyewiki.aao.org\/Acute_Retinal_Necrosis. Accessed 5 Mar 2024."},{"issue":"5","key":"990_CR30","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac118","volume":"9","author":"A Bhavsar","year":"2022","unstructured":"Bhavsar A, Lonnet G, Wang C, et al. Increased risk of herpes zoster in adults \u226550\u00a0years old diagnosed with COVID-19 in the United States. Open Forum Infect Dis. 2022;9(5):ofac118.","journal-title":"Open Forum Infect Dis"},{"key":"990_CR31","unstructured":"L\u00f3pez-Lacort M, Correcher-Mart\u00ednez E, Mu\u00f1oz-Quiles C, D\u00edez-Domingo J, Orrico A. Risk of herpes zoster in individuals diagnosed with SARS-CoV2 infection in the Valencia region of Spain: a retrospective cohort population-based study. Abstract P2443 and poster. 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Copenhagen, Denmark; 2023."},{"issue":"12","key":"990_CR32","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1056\/NEJMoa2110475","volume":"385","author":"N Barda","year":"2021","unstructured":"Barda N, Dagan N, Ben-Shlomo Y, et al. Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting. N Engl J Med. 2021;385(12):1078\u201390.","journal-title":"N Engl J Med"},{"issue":"5","key":"990_CR33","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1080\/14760584.2022.2044799","volume":"21","author":"M Gringeri","year":"2022","unstructured":"Gringeri M, Battini V, Cammarata G, et al. Herpes zoster and simplex reactivation following COVID-19 vaccination: new insights from a vaccine adverse event reporting system (VAERS) database analysis. Expert Rev Vaccines. 2022;21(5):675\u201384.","journal-title":"Expert Rev Vaccines"},{"key":"990_CR34","volume":"21","author":"EYF Wan","year":"2022","unstructured":"Wan EYF, Chui CSL, Wang Y, et al. Herpes zoster related hospitalization after inactivated (CoronaVac) and mRNA (BNT162b2) SARS-CoV-2 vaccination: a self-controlled case series and nested case-control study. Lancet Reg Health West Pac. 2022;21:100393.","journal-title":"Lancet Reg Health West Pac"},{"issue":"5","key":"990_CR35","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1080\/09273948.2022.2046795","volume":"30","author":"KI Rallis","year":"2022","unstructured":"Rallis KI, Fausto R, Ting DSJ, Al-Aqaba MA, Said DG, Dua HS. Manifestation of herpetic eye disease after COVID-19 vaccine: a UK case series. Ocul Immunol Inflamm. 2022;30(5):1136\u201341.","journal-title":"Ocul Immunol Inflamm"},{"issue":"22","key":"990_CR36","doi-asserted-by":"publisher","first-page":"6828","DOI":"10.3390\/jcm11226828","volume":"11","author":"LY Huang","year":"2022","unstructured":"Huang LY, Chiang CC, Li YL, et al. Corneal complications after COVID-19 vaccination: a systemic review. J Clin Med. 2022;11(22):6828.","journal-title":"J Clin Med"},{"issue":"11","key":"990_CR37","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.3390\/vaccines10111879","volume":"10","author":"P Ichhpujani","year":"2022","unstructured":"Ichhpujani P, Parmar UPS, Duggal S, Kumar S. COVID-19 vaccine-associated ocular adverse effects: an overview. Vaccines (Basel). 2022;10(11):1879.","journal-title":"Vaccines (Basel)"},{"issue":"2","key":"990_CR38","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1097\/WNO.0000000000001537","volume":"42","author":"I Lotan","year":"2022","unstructured":"Lotan I, Lydston M, Levy M. Neuro-ophthalmological complications of the COVID-19 vaccines: a systematic review. J Neuroophthalmol. 2022;42(2):154\u201362.","journal-title":"J Neuroophthalmol"},{"issue":"3","key":"990_CR39","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s40121-024-00924-3","volume":"13","author":"R Parikh","year":"2024","unstructured":"Parikh R, Yousefi M, Curran D, Widenmaier R. The impact of the COVID-19 pandemic on the incidence of herpes zoster: a narrative literature review. Infect Dis Ther. 2024;13(3):447\u201361.","journal-title":"Infect Dis Ther"},{"key":"990_CR40","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ajo.2023.07.004","volume":"258","author":"I Akpandak","year":"2024","unstructured":"Akpandak I, Sechrist SJ, Claire Miller D, et al. Risk of herpes zoster ophthalmicus after COVID-19 vaccination in a large US health care claims database. Am J Ophthalmol. 2024;258:139\u201344.","journal-title":"Am J Ophthalmol"},{"key":"990_CR41","unstructured":"Minor M, Payne E. Herpes zoster ophthalmicus. Treasure Island (FL): StatPearls; 2023."},{"issue":"8","key":"990_CR42","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1097\/ICO.0000000000002754","volume":"40","author":"EJ Cohen","year":"2021","unstructured":"Cohen EJ, Jeng BH. Herpes zoster: a brief definitive review. Cornea. 2021;40(8):943\u20139.","journal-title":"Cornea"},{"issue":"5","key":"990_CR43","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1136\/bjo.71.5.353","volume":"71","author":"SP Harding","year":"1987","unstructured":"Harding SP, Lipton JR, Wells JC. Natural history of herpes zoster ophthalmicus: predictors of postherpetic neuralgia and ocular involvement. Br J Ophthalmol. 1987;71(5):353\u20138.","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"990_CR44","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.mayocp.2013.03.014","volume":"88","author":"BP Yawn","year":"2013","unstructured":"Yawn BP, Wollan PC, St Sauver JL, Butterfield LC. Herpes zoster eye complications: rates and trends. Mayo Clin Proc. 2013;88(6):562\u201370.","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"990_CR45","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1097\/ICO.0000000000001046","volume":"36","author":"SK Szeto","year":"2017","unstructured":"Szeto SKH, Chan TCY, Wong RLM, Ng ALK, Li EYM, Jhanji V. Prevalence of ocular manifestations and visual outcomes in patients with herpes zoster ophthalmicus. Cornea. 2017;36(3):338\u201342.","journal-title":"Cornea"},{"key":"990_CR46","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ajo.2021.02.002","volume":"226","author":"RL Niederer","year":"2021","unstructured":"Niederer RL, Meyer JJ, Liu K, Danesh-Meyer HV. Herpes zoster ophthalmicus clinical presentation and risk factors for loss of vision. Am J Ophthalmol. 2021;226:83\u20139.","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"990_CR47","doi-asserted-by":"publisher","first-page":"226","DOI":"10.5694\/mja2.50554","volume":"213","author":"R Chakrabarti","year":"2020","unstructured":"Chakrabarti R, George G, Wells K, Crock C, Fahy E. Characteristics, treatment and complications of herpes zoster ophthalmicus at a tertiary eye hospital. Med J Aust. 2020;213(5):226\u20137.","journal-title":"Med J Aust"},{"key":"990_CR48","unstructured":"The Royal Victorian Eye and Ear Hospital. Clinical practice guideline. Emergency department. Herpes zoster ophthalmicus. https:\/\/eyeandear.org.au\/wp-content\/uploads\/2021\/11\/Herpes-Zoster-Ophthalmicus-Clinical-Practice-Guideline1.pdf. Accessed 5 Mar 2024."},{"key":"990_CR49","doi-asserted-by":"publisher","first-page":"1094044","DOI":"10.3389\/fcell.2022.1094044","volume":"10","author":"X Yu","year":"2022","unstructured":"Yu X, Jia X, Zhang Z, et al. Meibomian gland morphological changes in ocular herpes zoster patients based on AI analysis. Front Cell Dev Biol. 2022;10:1094044.","journal-title":"Front Cell Dev Biol"},{"issue":"2","key":"990_CR50","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.ajo.2009.08.030","volume":"149","author":"AY Hu","year":"2010","unstructured":"Hu AYH, Strauss EC, Holland GN, Chan MF, Yu F, Margolis TP. Late varicella-zoster virus dendriform keratitis in patients with histories of herpes zoster ophthalmicus. Am J Ophthalmol. 2010;149(2):214\u201320.e3.","journal-title":"Am J Ophthalmol"},{"issue":"11","key":"990_CR51","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1136\/bjo.67.11.751","volume":"67","author":"A Reijo","year":"1983","unstructured":"Reijo A, Antti V, Jukka M. Endothelial cell loss in herpes zoster keratouveitis. Br J Ophthalmol. 1983;67(11):751\u20134.","journal-title":"Br J Ophthalmol"},{"issue":"8","key":"990_CR52","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1097\/ICO.0000000000001235","volume":"36","author":"OM Hassan","year":"2017","unstructured":"Hassan OM, Farooq AV, Soin K, Djalilian AR, Hou JH. Management of corneal scarring secondary to herpes zoster keratitis. Cornea. 2017;36(8):1018\u201323.","journal-title":"Cornea"},{"key":"990_CR53","unstructured":"Feldman BH, Bunya VY, Woodward MA, et al. EyeWiki. Herpes zoster ophthalmicus. American Academy of Ophthalmology. https:\/\/eyewiki.aao.org\/Herpes_Zoster_Ophthalmicus. Accessed 5 Mar 2024."},{"issue":"11","key":"990_CR54","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1097\/ICO.0000000000003003","volume":"41","author":"JJ Meyer","year":"2022","unstructured":"Meyer JJ, Liu K, McGhee CNJ, Danesh-Meyer HV, Niederer RL. Neurotrophic keratopathy after herpes zoster ophthalmicus. Cornea. 2022;41(11):1433\u20136.","journal-title":"Cornea"},{"issue":"2","key":"990_CR55","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3341\/kjo.2021.0164","volume":"36","author":"M Kim","year":"2022","unstructured":"Kim M, Chun YS, Moon NJ, Kim KW. Clinical factors associated with the early reduction of corneal sensitivity in herpes zoster ophthalmicus. Korean J Ophthalmol. 2022;36(2):147\u201353.","journal-title":"Korean J Ophthalmol"},{"key":"990_CR56","unstructured":"O'Keefe GD, Patel N, Hurzhii O. EyeWiki. Herpes zoster uveitis. American American Academy of Ophthalmology. https:\/\/eyewiki.aao.org\/Herpes_Zoster_Uveitis. https:\/\/eyewiki.aao.org\/Herpes_Zoster_Uveitis. Accessed 27 Mar 2024."},{"issue":"4","key":"990_CR57","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.ophtha.2006.08.037","volume":"114","author":"CH Lau","year":"2007","unstructured":"Lau CH, Missotten T, Salzmann J, Lightman SL. Acute retinal necrosis: features, management, and outcomes. Ophthalmology. 2007;114(4):756\u201362.e1.","journal-title":"Ophthalmology"},{"key":"990_CR58","doi-asserted-by":"publisher","DOI":"10.3389\/fopht.2022.916113","author":"F Hoogewoud","year":"2022","unstructured":"Hoogewoud F, Rossi DC, Stappler T, Guex-Crosier Y. Acute retinal necrosis: a mini review. Front Ophthalmol. 2022. https:\/\/doi.org\/10.3389\/fopht.2022.916113.","journal-title":"Front Ophthalmol"},{"issue":"4","key":"990_CR59","doi-asserted-by":"publisher","first-page":"946","DOI":"10.3390\/jcm9040946","volume":"9","author":"PW Tsau","year":"2020","unstructured":"Tsau PW, Liao MF, Hsu JL, et al. Clinical presentations and outcome studies of cranial nerve involvement in herpes zoster infection: a retrospective single-center analysis. J Clin Med. 2020;9(4):946.","journal-title":"J Clin Med"},{"issue":"4","key":"990_CR60","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1097\/OPX.0000000000001204","volume":"95","author":"E Bak","year":"2018","unstructured":"Bak E, Kim N, Khwarg SI, Choung HK. Case series: herpes zoster ophthalmicus with acute orbital inflammation. Optom Vis Sci. 2018;95(4):405\u201310.","journal-title":"Optom Vis Sci"},{"key":"990_CR61","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.ajo.2021.03.020","volume":"227","author":"Y Terada","year":"2021","unstructured":"Terada Y, Kaburaki T, Takase H, et al. Distinguishing features of anterior uveitis caused by herpes simplex virus, varicella-zoster virus, and cytomegalovirus. Am J Ophthalmol. 2021;227:191\u2013200.","journal-title":"Am J Ophthalmol"},{"issue":"9","key":"990_CR62","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1111\/j.1442-9071.2010.02352.x","volume":"38","author":"S Nithyanandam","year":"2010","unstructured":"Nithyanandam S, Stephen J, Joseph M, Dabir S. Factors affecting visual outcome in herpes zoster ophthalmicus: a prospective study. Clin Exp Ophthalmol. 2010;38(9):845\u201350.","journal-title":"Clin Exp Ophthalmol"},{"issue":"10","key":"990_CR63","doi-asserted-by":"publisher","first-page":"999","DOI":"10.3390\/medicina57100999","volume":"57","author":"SM Lee","year":"2021","unstructured":"Lee SM, Han J, Yang CM, et al. Chronic and recurrent herpes zoster ophthalmicus. Medicina (Kaunas). 2021;57(10):999.","journal-title":"Medicina (Kaunas)"},{"issue":"7","key":"990_CR64","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1016\/j.ophtha.2016.03.005","volume":"123","author":"KD Tran","year":"2016","unstructured":"Tran KD, Falcone MM, Choi DS, et al. Epidemiology of herpes zoster ophthalmicus: recurrence and chronicity. Ophthalmology. 2016;123(7):1469\u201375.","journal-title":"Ophthalmology"},{"issue":"6","key":"990_CR65","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.jcrs.2019.01.003","volume":"45","author":"LM Lu","year":"2019","unstructured":"Lu LM, McGhee CNJ, Sims JL, Niederer RL. High rate of recurrence of herpes zoster-related ocular disease after phacoemulsification cataract surgery. J Cataract Refract Surg. 2019;45(6):810\u20135.","journal-title":"J Cataract Refract Surg"},{"issue":"1","key":"990_CR66","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/jdv.13995","volume":"31","author":"RN Werner","year":"2017","unstructured":"Werner RN, Nikkels AF, Marinovic B, et al. European consensus-based (S2k) guideline on the management of herpes zoster\u2014guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV), part 1: diagnosis. J Eur Acad Dermatol Venereol. 2017;31(1):9\u201319.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"990_CR67","doi-asserted-by":"publisher","first-page":"403","DOI":"10.3344\/kjp.2020.33.4.403","volume":"33","author":"HH Al-Ani","year":"2020","unstructured":"Al-Ani HH, Niederer RL. Zoster sine herpete: a disease that ophthalmologists should be aware of. Korean J Pain. 2020;33(4):403\u20134.","journal-title":"Korean J Pain"},{"issue":"12","key":"990_CR68","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.18240\/ijo.2021.12.21","volume":"14","author":"M Goswami","year":"2021","unstructured":"Goswami M, Bhattacharya S, Bandyopadhyay M. Ocular manifestation and visual outcomes in herpes zoster ophthalmicus: a prospective study from a tertiary hospital of Eastern India. Int J Ophthalmol. 2021;14(12):1950\u20136.","journal-title":"Int J Ophthalmol"},{"issue":"1","key":"990_CR69","first-page":"6","volume":"43","author":"A Lu","year":"2024","unstructured":"Lu A, Sun Y, Porco TC, Arnold BF, Acharya NR. Practice patterns in the initial management of herpes zoster ophthalmicus in the United States. Cornea. 2024;43(1):6\u201312.","journal-title":"Cornea"},{"issue":"1","key":"990_CR70","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/jdv.13957","volume":"31","author":"RN Werner","year":"2017","unstructured":"Werner RN, Nikkels AF, Marinovic B, et al. European consensus-based (S2k) guideline on the management of herpes zoster\u2014guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV), part 2: treatment. J Eur Acad Dermatol Venereol. 2017;31(1):20\u20139.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"990_CR71","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1093\/clinids\/22.2.341","volume":"22","author":"MJ Wood","year":"1996","unstructured":"Wood MJ, Kay R, Dworkin RH, Soong SJ, Whitley RJ. Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: a meta-analysis of placebo-controlled trials. Clin Infect Dis. 1996;22(2):341\u20137.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"990_CR72","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1001\/archinte.1997.00440290095010","volume":"157","author":"JL Jackson","year":"1997","unstructured":"Jackson JL, Gibbons R, Meyer G, Inouye L. The effect of treating herpes zoster with oral acyclovir in preventing postherpetic neuralgia. A meta-analysis. Arch Intern Med. 1997;157(8):909\u201312.","journal-title":"Arch Intern Med"},{"issue":"2","key":"990_CR73","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1071\/HC14108","volume":"6","author":"KA Wallis","year":"2014","unstructured":"Wallis KA, Hood LJ, Rao K. Herpes zoster: when do patients present and who gets antiviral treatment? J Prim Health Care. 2014;6(2):108\u201313.","journal-title":"J Prim Health Care"},{"issue":"7","key":"990_CR74","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/S0161-6420(92)31849-4","volume":"99","author":"T Hoang-Xuan","year":"1992","unstructured":"Hoang-Xuan T, B\u00fcchi ER, Herbort CP, et al. Oral acyclovir for herpes zoster ophthalmicus. Ophthalmology. 1992;99(7):1062\u201371.","journal-title":"Ophthalmology"},{"issue":"1","key":"990_CR75","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1136\/bjophthalmol-2015-306700","volume":"100","author":"EJ Cohen","year":"2016","unstructured":"Cohen EJ, Kessler J. Persistent dilemmas in zoster eye disease. Br J Ophthalmol. 2016;100(1):56\u201361.","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"990_CR76","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1001\/archopht.121.3.386","volume":"121","author":"EA Severson","year":"2003","unstructured":"Severson EA, Baratz KH, Hodge DO, Burke JP. Herpes zoster ophthalmicus in olmsted county, Minnesota: have systemic antivirals made a difference? Arch Ophthalmol. 2003;121(3):386\u201390.","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"990_CR77","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jcjo.2017.08.005","volume":"53","author":"S Fan","year":"2018","unstructured":"Fan S, Stojanovic D, Malvankar-Mehta MS, Hutnik C. Treatment of herpes zoster ophthalmicus: a systematic review and Canadian cost-comparison. Can J Ophthalmol. 2018;53(2):117\u201323.","journal-title":"Can J Ophthalmol"},{"issue":"1","key":"990_CR78","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/ICO.0000000000001732","volume":"38","author":"DM Lo","year":"2019","unstructured":"Lo DM, Jeng BH, Gillespie C, Wu M, Cohen EJ. Current practice patterns and opinions on the management of recent-onset or chronic herpes zoster ophthalmicus of Zoster Eye Disease Study Investigators. Cornea. 2019;38(1):13\u20137.","journal-title":"Cornea"},{"issue":"11","key":"990_CR79","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1136\/bjo.2007.114884","volume":"91","author":"MN Muthiah","year":"2007","unstructured":"Muthiah MN, Michaelides M, Child CS, Mitchell SM. Acute retinal necrosis: a national population-based study to assess the incidence, methods of diagnosis, treatment strategies and outcomes in the UK. Br J Ophthalmol. 2007;91(11):1452\u20135.","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"990_CR80","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1136\/bjophthalmol-2012-301983","volume":"97","author":"RW Wong","year":"2013","unstructured":"Wong RW, Jumper JM, McDonald HR, et al. Emerging concepts in the management of acute retinal necrosis. Br J Ophthalmol. 2013;97(5):545\u201352.","journal-title":"Br J Ophthalmol"},{"key":"990_CR81","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.2147\/OPTH.S60394","volume":"9","author":"U Pleyer","year":"2015","unstructured":"Pleyer U, Chee SP. Current aspects on the management of viral uveitis in immunocompetent individuals. Clin Ophthalmol. 2015;9:1017\u201328.","journal-title":"Clin Ophthalmol"},{"issue":"2","key":"990_CR82","doi-asserted-by":"publisher","first-page":"386","DOI":"10.3390\/diagnostics12020386","volume":"12","author":"CS Mayer","year":"2022","unstructured":"Mayer CS, Blobner K, Storr J, Baur ID, Khoramnia R. Acute retinal necrosis: signs, treatment, complications and outcome. Diagnostics (Basel). 2022;12(2):386.","journal-title":"Diagnostics (Basel)"},{"key":"990_CR83","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k5095","volume":"364","author":"P Le","year":"2019","unstructured":"Le P. Herpes zoster infection. BMJ. 2019;364:k5095.","journal-title":"BMJ"},{"issue":"5","key":"990_CR84","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1097\/ICO.0000000000002743","volume":"41","author":"EJ Cohen","year":"2022","unstructured":"Cohen EJ, Hochman JS, Troxel AB, Colby KA, Jeng BH; ZEDS Trial Research Group. Zoster Eye Disease Study: rationale and design. Cornea. 2022;41(5):562\u201371.","journal-title":"Cornea"},{"key":"990_CR85","unstructured":"Zoster Eye Disease Study (ZEDS). ClinicalTrials.gov ID NCT03134196. https:\/\/clinicaltrials.gov\/study\/NCT03134196. Accessed 28 Feb 2024."},{"issue":"3","key":"990_CR86","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.ophtha.2019.12.017","volume":"127","author":"EJ Cohen","year":"2020","unstructured":"Cohen EJ. Incidence rate of herpes zoster ophthalmicus. Ophthalmology. 2020;127(3):331\u20132.","journal-title":"Ophthalmology"},{"key":"990_CR87","doi-asserted-by":"crossref","first-page":"251513552210845","DOI":"10.1177\/25151355221084535","volume":"10","author":"CX Pan","year":"2022","unstructured":"Pan CX, Lee MS, Nambudiri VE. Global herpes zoster incidence, burden of disease, and vaccine availability: a narrative review. Ther Adv Vaccines Immunother. 2022;10:25151355221084535.","journal-title":"Ther Adv Vaccines Immunother"},{"issue":"6","key":"990_CR88","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1093\/cid\/ciu918","volume":"60","author":"VA Morrison","year":"2015","unstructured":"Morrison VA, Johnson GR, Schmader KE, et al. Long-term persistence of zoster vaccine efficacy. Clin Infect Dis. 2015;60(6):900\u20139.","journal-title":"Clin Infect Dis"},{"key":"990_CR89","unstructured":"Merck & Co., Inc. Zostavax (Zoster Vaccine Live), suspension for subcutaneous injection. Highlights of Prescribing Information. https:\/\/www.fda.gov\/media\/82524\/download#:~:text=Administer%20ZOSTAVAX%20as%20a%20single,region%20of%20the%20upper%20arm.&text=subcutaneously.&text=ADMINISTER%20IMMEDIATELY%20AFTER%20RECONSTITUTION%20to,not%20used%20within%2030%20minutes. Accessed 19 Oct 2023."},{"key":"990_CR90","unstructured":"Zostavax. Summary of Product Characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/zostavax-epar-product-information_en.pdf. Accessed 27 Mar 2024."},{"key":"990_CR91","unstructured":"Shingrix (Zoster Vaccine Recombinant, Adjuvanted), suspension for intramuscular injection. https:\/\/gskpro.com\/content\/dam\/global\/hcpportal\/en_US\/Prescribing_Information\/Shingrix\/pdf\/SHINGRIX.PDF. Accessed 24 Apr 2023."},{"key":"990_CR92","unstructured":"Shingrix. Summary of Product Characteristics. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/shingrix. Accessed 24 Apr 2023."},{"issue":"12","key":"990_CR93","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1016\/j.vaccine.2018.02.029","volume":"36","author":"M Kovac","year":"2018","unstructured":"Kovac M, Lal H, Cunningham AL, et al. Complications of herpes zoster in immunocompetent older adults: incidence in vaccine and placebo groups in two large phase\u00a03 trials. Vaccine. 2018;36(12):1537\u201341.","journal-title":"Vaccine"},{"issue":"10","key":"990_CR94","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac485","volume":"9","author":"A Strezova","year":"2022","unstructured":"Strezova A, Diez-Domingo J, Al Shawafi K, et al. Long-term protection against herpes zoster by the adjuvanted recombinant zoster vaccine: interim efficacy, immunogenicity, and safety results up to 10\u00a0years after initial vaccination. Open Forum Infect Dis. 2022;9(10):ofac485.","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"990_CR95","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1001\/jama.2019.9053","volume":"322","author":"A Bastidas","year":"2019","unstructured":"Bastidas A, de la Serna J, El Idrissi M, et al. Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation: a randomized clinical trial. JAMA. 2019;322(2):123\u201333.","journal-title":"JAMA"},{"issue":"9","key":"990_CR96","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/S1473-3099(19)30163-X","volume":"19","author":"AF Dagnew","year":"2019","unstructured":"Dagnew AF, Ilhan O, Lee WS, et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase\u00a03, randomised, clinical trial and post-hoc efficacy analysis. Lancet Infect Dis. 2019;19(9):988\u20131000.","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"990_CR97","doi-asserted-by":"publisher","first-page":"e263","DOI":"10.1016\/S2666-7568(22)00039-3","volume":"3","author":"JF Mbinta","year":"2022","unstructured":"Mbinta JF, Nguyen BP, Awuni PMA, Paynter J, Simpson CR. Post-licensure zoster vaccine effectiveness against herpes zoster and postherpetic neuralgia in older adults: a systematic review and meta-analysis. Lancet Healthy Longev. 2022;3(4):e263\u201375.","journal-title":"Lancet Healthy Longev"},{"key":"990_CR98","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k4029","volume":"363","author":"AC Tricco","year":"2018","unstructured":"Tricco AC, Zarin W, Cardoso R, et al. Efficacy, effectiveness, and safety of herpes zoster vaccines in adults aged 50 and older: systematic review and network meta-analysis. BMJ. 2018;363:k4029.","journal-title":"BMJ"},{"key":"990_CR99","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076321","volume":"383","author":"NP Klein","year":"2023","unstructured":"Klein NP, Bartlett J, Fireman B, et al. Effectiveness of the live zoster vaccine during the 10\u00a0years following vaccination: real world cohort study using electronic health records. BMJ. 2023;383:e076321.","journal-title":"BMJ"},{"issue":"6","key":"990_CR100","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1093\/cid\/ciab125","volume":"73","author":"HS Izurieta","year":"2021","unstructured":"Izurieta HS, Wu X, Forshee R, et al. Recombinant zoster vaccine (Shingrix): real-world effectiveness in the first 2\u00a0years post-licensure. Clin Infect Dis. 2021;73(6):941\u20138.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"990_CR101","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1016\/j.ophtha.2021.04.017","volume":"128","author":"A Lu","year":"2021","unstructured":"Lu A, Sun Y, Porco TC, Arnold BF, Acharya NR. Effectiveness of the recombinant zoster vaccine for herpes zoster ophthalmicus in the United States. Ophthalmology. 2021;128(12):1699\u2013707.","journal-title":"Ophthalmology"},{"issue":"29","key":"990_CR102","doi-asserted-by":"publisher","first-page":"3974","DOI":"10.1016\/j.vaccine.2021.05.056","volume":"39","author":"Y Sun","year":"2021","unstructured":"Sun Y, Jackson K, Dalmon CA, et al. Effectiveness of the recombinant zoster vaccine among Kaiser Permanente Hawaii enrollees aged 50 and older: a retrospective cohort study. Vaccine. 2021;39(29):3974\u201382.","journal-title":"Vaccine"},{"issue":"3","key":"990_CR103","doi-asserted-by":"publisher","first-page":"103","DOI":"10.15585\/mmwr.mm6703a5","volume":"67","author":"KL Dooling","year":"2018","unstructured":"Dooling KL, Guo A, Patel M, et al. Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines. MMWR Morb Mortal Wkly Rep. 2018;67(3):103\u20138.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"3","key":"990_CR104","doi-asserted-by":"publisher","first-page":"80","DOI":"10.15585\/mmwr.mm7103a2","volume":"71","author":"TC Anderson","year":"2022","unstructured":"Anderson TC, Masters NB, Guo A, et al. Use of recombinant zoster vaccine in immunocompromised adults aged \u226519\u00a0years: recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(3):80\u20134.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"990_CR105","unstructured":"Australian Technical Advisory Group on Immunisation (ATAGI). Clinical Advice. Version 2.1 Issue date 26 April 2022. Statement on the clinical use of sozter vaccines in adults in Australia. https:\/\/www.health.gov.au\/sites\/default\/files\/documents\/2022\/05\/statement-on-the-clinical-use-of-zoster-vaccine-in-older-adults-in-australia-statement-on-the-clinical-use-of-zoster-vaccine-in-older-adults-in-australia.pdf. Accessed 5 Dec 2023."},{"key":"990_CR106","unstructured":"Government of Canada. Herpes zoster (shingles) vaccine: Canadian Immunization Guide. Public Health Agency of Canada. Date modified 2022\u201301\u201320. https:\/\/www.canada.ca\/en\/public-health\/services\/publications\/healthy-living\/canadian-immunization-guide-part-4-active-vaccines\/page-8-herpes-zoster-(shingles)-vaccine.html#a5. Accessed 15 May 2023."},{"issue":"3","key":"990_CR107","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1007\/s00103-019-02882-5","volume":"62","author":"A Siedler","year":"2019","unstructured":"Siedler A, Koch J, Garbe E, et al. Background paper to the decision to recommend the vaccination with the inactivated herpes zoster subunit vaccine: statement of the German Standing Committee on Vaccination (STIKO) at the Robert Koch Institute. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2019;62(3):352\u201376.","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"key":"990_CR108","unstructured":"American Academy of Ophthalmology. Policy statement. Recommendations for herpes zoster vaccine for patients 50 years of age and older. Revised June 2018. https:\/\/www.aao.org\/education\/clinical-statement\/recommendations-herpes-zoster-vaccine-patients-50-#:~:text=Ophthalmologists%20should%20recommend%20strongly%20that,recommend%20vaccination%20strongly%20against%20herpes. Accessed 10 Mar 2024."},{"issue":"4","key":"990_CR109","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1097\/ICO.0b013e318277acae","volume":"32","author":"CW Hwang Jr","year":"2013","unstructured":"Hwang CW Jr., Steigleman WA, Saucedo-Sanchez E, Tuli SS. Reactivation of herpes zoster keratitis in an adult after varicella zoster vaccination. Cornea. 2013;32(4):508\u20139.","journal-title":"Cornea"},{"issue":"6","key":"990_CR110","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1097\/ICO.0000000000001203","volume":"36","author":"A Jastrzebski","year":"2017","unstructured":"Jastrzebski A, Brownstein S, Ziai S, Saleh S, Lam K, Jackson WB. Reactivation of herpes zoster keratitis with corneal perforation after zoster vaccination. Cornea. 2017;36(6):740\u20132.","journal-title":"Cornea"},{"issue":"1","key":"990_CR111","volume":"15","author":"F Altukhaim","year":"2023","unstructured":"Altukhaim F, Mutlaq M, Alghamdi M, Hakami S. Reactivation of herpes zoster after recombinant vaccine (Shingrix): a case report. Cureus. 2023;15(1):e34431.","journal-title":"Cureus"},{"key":"990_CR112","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2021.101115","volume":"23","author":"PJ Richards","year":"2021","unstructured":"Richards PJ, Wingelaar MJ, Armbrust KR, Kopplin LJ. Uveitis reactivation following recombinant zoster vaccination. Am J Ophthalmol Case Rep. 2021;23:101115.","journal-title":"Am J Ophthalmol Case Rep"},{"key":"990_CR113","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2023.6830","author":"A Walia","year":"2024","unstructured":"Walia A, Sun Y, Acharya NR. Risk of herpes zoster ophthalmicus recurrence after recombinant zoster vaccination. JAMA Ophthalmol. 2024;142(3):249\u201356.","journal-title":"JAMA Ophthalmol"},{"key":"990_CR114","unstructured":"Litt J, Cunningham T, Van Buynder P. Update on herpes zoster. Healthed expert monograph, issue 18. 2018. https:\/\/www.healthed.com.au\/wp-content\/uploads\/2018\/01\/Monograph-No-18-Final-Updated.pdf. Accessed 2 Aug 2023."},{"key":"990_CR115","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.ijid.2014.03.1320","volume":"21","author":"JCB Litt","year":"2014","unstructured":"Litt JCB, Kim S, Woodman R, MacIntyre R, Cunningham T. Australian zoster study: GP and patient views about herpes zoster (shingles), its complications, and the likely acceptance of a zoster vaccine (Zostavax). Int J Infect Dis. 2014;21:436\u20137.","journal-title":"Int J Infect Dis"},{"issue":"12","key":"990_CR116","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.1080\/21645515.2020.1754702","volume":"16","author":"J Litt","year":"2020","unstructured":"Litt J, Booy R, Bourke D, et al. Early impact of the Australian national shingles vaccination program with the herpes zoster live attenuated vaccine. Hum Vaccin Immunother. 2020;16(12):3081\u20139.","journal-title":"Hum Vaccin Immunother"},{"issue":"2 Suppl","key":"990_CR117","first-page":"16","volume":"20","author":"J Litt","year":"2019","unstructured":"Litt J, Cunningham AL. Herpes zoster. Improving protection in older people. Med Today. 2019;20(2 Suppl):16\u201322.","journal-title":"Med Today"},{"key":"990_CR118","unstructured":"Institut national d\u2019excellence en sant\u00e9 et en services sociaux Qu\u00e9bec. Herpes zoster ophthalmicus. https:\/\/www.inesss.qc.ca\/fileadmin\/doc\/INESSS\/Outils\/GUO\/Zona\/Guide_ZonaOphtalmique_web_EN_VF.pdf. Accessed 5 Mar 2024."},{"issue":"Suppl 10","key":"990_CR119","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1097\/ICO.0000000000000503","volume":"34","author":"EJ Cohen","year":"2015","unstructured":"Cohen EJ. Management and prevention of herpes zoster ocular disease. Cornea. 2015;34(Suppl 10):S3\u20138.","journal-title":"Cornea"},{"key":"990_CR120","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12348-014-0025-9","volume":"4","author":"R Kahloun","year":"2014","unstructured":"Kahloun R, Attia S, Jelliti B, et al. Ocular involvement and visual outcome of herpes zoster ophthalmicus: review of 45 patients from Tunisia. North Africa J Ophthalmic Inflamm Infect. 2014;4:25.","journal-title":"North Africa J Ophthalmic Inflamm Infect"},{"issue":"3","key":"990_CR121","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1034\/j.1600-0420.2003.00057.x","volume":"81","author":"MJ Zaal","year":"2003","unstructured":"Zaal MJ, V\u00f6lker-Dieben HJ, D\u2019Amaro J. Visual prognosis in immunocompetent patients with herpes zoster ophthalmicus. Acta Ophthalmol Scand. 2003;81(3):216\u201320.","journal-title":"Acta Ophthalmol Scand"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-024-00990-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-024-00990-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-024-00990-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T02:03:40Z","timestamp":1719885820000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-024-00990-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,4]]},"references-count":121,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["990"],"URL":"https:\/\/doi.org\/10.1007\/s40121-024-00990-7","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,4]]},"assertion":[{"value":"17 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"John Litt has received payment and\/or honoraria from GSK, Merck, Pfizer, Sanofi, and Seqirus, and served as a member of the Immunisation Coalition Scientific Advisory Committee. Anthony L. Cunningham\u2019s institution has received payment and\/or honoraria from AbbVie, Curevo, GSK, HealthEd, Merck, Moderna, and Seqirus. Francisco Arnalich-Montiel has no conflicts of interest to disclose. Raunak Parikh is an employee of GSK and holds stock or stock options.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}